Viracta Therapeutics Inc (VIRX)

NASDAQ
2.65
-0.11(-3.99%)
After Hours
2.96
+0.31(+11.70%)
- Real-time Data
  • Volume:
    173,167
  • Bid/Ask:
    0.00/0.00
  • Day's Range:
    2.64 - 2.85

VIRX Overview

Prev. Close
2.76
Day's Range
2.64-2.85
Revenue
-
Open
2.76
52 wk Range
2.65-24.8
EPS
-6.8
Volume
173,167
Market Cap
98.88M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
219,360
P/E Ratio
-
Beta
2.16
1-Year Change
-75.34%
Shares Outstanding
37,311,690
Next Earnings Date
May 12, 2022
What is your sentiment on Viracta Therapeutics Inc?
or
Market is currently closed. Voting is open during market hours.

Viracta Therapeutics Inc Company Profile

Employees
24

Viracta Therapeutics, Inc., formerly Sunesis Pharmaceuticals, Inc., is a precision oncology company. The Company is focused on the development of new medicines targeting virus-associated malignancies. The Company conducts clinical trials for its combination product candidate as a therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The Company is conducting three clinical trials for its lead product candidate, Nana-val, in EBV+ lymphomas and solid tumors, including a Phase II registrational trial of Nana-val in EBV+ lymphomas. Its lead product candidate is an all-oral combination of nanatinostat. Its development pipeline also includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510, a preclinical-stage PDK-1 inhibitor. Its novel synthetic lethality approach targets the EBV genome to enable the killing of the tumor cells by inducing the expression of certain viral kinase genes which in-turn activate an antiviral drug.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellStrong SellStrong Sell
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Sell
SummaryStrong SellStrong SellStrong SellStrong SellStrong Sell
  • Has anyone else seen the sec filings on company site 5-6 major sec filinggs for purchase of over 80k shares filed 3/30
    0
    • Pump and dump scheme, only made the private officers of Viracta rich on acquiring Sunesis pharma
      0
      • Going to reverse split 1:3.5 when it goes live again.
        0
        • today its change to merge VIRX
          0
          • If you like this stock, load up on MATn while it's cheap. A lot of development in the works, then most likely a move up to NASDAQ
            0
            • yesterday dip to 3.63..today pre market $5.00... woww
              0
              • Cocrystal Pharma, Inc. (NASDAQ:COCP) was in 4 hedge funds' portfolios at the end of the third quarter of 2020. The all time high for this statistics is 3. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. COCP has experienced an increase in hedge fund interest recently. There were 1 hedge funds in our database with COCP holdings at the end of June. Our calculations also showed that COCP isn't among the 30 most popular stocks among hedge funds  Premarket, +10%
                0
                • wow!!wat is going on!!skyrocket
                  0
                  • No body talks
                    0
                    • Here i am
                      0
                  • I hear JP Marlin is the boile- I mean investment firm that sells the most of this stock.
                    0
                    • holy ****i sold on the 30th!!!! wheew lad
                      0
                      • omg
                        0
                      • it was revers split or it truely pump up?
                        0
                      • cause i wanted to bouht on 2 of septemper xD
                        0
                    • why did the reverse stock split make the stock drop?
                      0
                      • the shareholders crapped themselves because it wasn't a B/O. possibly a r/s merger in the works though Dayton is a smart guy he has 100% success rate he isn't gonna let that break now
                        0
                    • bears cant look at it no more 😂
                      0
                      • Drop to $0.2
                        3
                        • https://themarketnewsreport.com/the-top-reasons-its-high-time-to-invest-in-the-24-billion-cbd-boom/
                          0
                          • NO NEWS...Earnings scheduled for After bell...company been pumping there stock up for a few days getting ready for the drop
                            0
                            • Q2 2020 Sunesis Pharmaceuticals Inc. Earnings today 4:30pm EDT.
                              0
                          • Any news
                            0
                            • this thing will drop hard AH with ER ...mark this post...
                              0
                              • https://themarketnewsreport.com/the-top-reasons-its-high-time-to-invest-in-the-24-billion-cbd-boom/
                                0
                            • 2 USD or more.. Soon
                              0
                              • Do you have any reason to expect 2 dollars?
                                0
                            • Welcome Robin Hood buyers.. Soon it will jump..
                              0
                              • Target 1.2 USD soon
                                1
                                • Will it rise after Earnings release?
                                  1
                                  • BOOM!
                                    0
                                    • defining week ahead will it raise or will it fall?
                                      2
                                      • beast mode!!!
                                        1
                                        Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                        Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.